Skip to Content

Anti-Infliximab Antibodies Led to Poorer Clinical Outcomes

Findings from a EULAR 2023 study reveal that the development of neutralizing anti-drug antibodies during infliximab induction and maintenance therapy contributes to poorer clinical outcomes. Listen to Marthe Kirkesæther Brun from the Department of Rheumatology at the Diakonhjemmet Hospital in Norway as she presents these results and explains the promising aspect of early detection of anti-drug antibodies through proactive TDM.

Marthe Kirkesæther Brun

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top